FindTrial
Sign In

Characteristics of novel coronavirus pneumonia (COVID-19) patients with mild nucleic acid in hospital for over 30 days

Characteristics of novel coronavirus pneumonia patients with mild nucleic acid in hospital for over 30 days

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040179
Enrollment
Unknown
Registered
2020-11-24
Start date
2020-01-01
Completion date
Unknown
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

The patients were divided into three groups according to the length of stay 1-14 days, 15-29 days and more than 30 days:Nil

Sponsors

Chongqing Shapingba District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 100 Years

Inclusion criteria

Inclusion criteria: Novel coronavirus pneumonia diagnosis and treatment plan (Trial Seventh Edition) was selected from 180 patients with mild diagnosis, including mild and general, who were diagnosed as COVID-19 in Xiaogan First People's Hospital isolation ward from January 2020 to April in Hubei.

Exclusion criteria

Exclusion criteria: The novel coronavirus pneumonia diagnostic and therapeutic plan (Trial Seventh Edition) is in line with the National Health Council's diagnostic criteria for critically ill patients or other patients.

Design outcomes

Primary

MeasureTime frame
nucleic acid test;—

Countries

China

Contacts

Public ContactHuang Zi-Yang

Chongqing Shapingba District People's Hospital

215136405@qq.com+86 21 65365104

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026